(Q34189214)

31 July 2017

1 reference

title

Therapeutic vaccines against melanoma and colorectal cancer (English)

1 reference

31 July 2017

1 reference

1 reference

1 reference

Tartaglia J

1

1 reference

31 July 2017

Bonnet MC

2

1 reference

31 July 2017

Berinstein N

3

1 reference

31 July 2017

Barber B

4

1 reference

31 July 2017

Klein M

5

1 reference

31 July 2017

Moingeon P

6

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

19

1 reference

31 July 2017

issue

17-19

1 reference

31 July 2017

page(s)

2571-2575

1 reference

New tumor antigens recognized by T cells

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Cancer vaccines based on the identification of genes encoding cancer regression antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

A new era for cancer immunotherapy based on the genes that encode cancer antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

New paths in human cancer serology

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

1 reference

7 January 2021

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Recombinant viruses as a tool for therapeutic vaccination against human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

The prime-boost strategy: exciting prospects for improved vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Applications of pox virus vectors to vaccination: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900491-6

7 January 2021

10.1016/S0264-410X(00)00491-6

Identifiers

DOI

1 reference

31 July 2017

1 reference